The Indonesia Clinical Laboratory Services Market is expected to grow with a CAGR of 5.5% in the forecast period of 2021 to 2028. The years considered for the study are as mentioned below:
Access Full Report @ https://www.databridgemarketresearch.com/reports/indonesia-clinical-laboratory-services-market
The Indonesia clinical laboratory services market is a highly consolidated market, including a specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenarios.
The major players dealing in the Indonesia clinical laboratory services market are introducing a strong range of products provider along with launching new products and adopting strategic initiatives such as mergers, partnerships, and agreements into the market. This helped companies to maximize sales with an enhanced product portfolio.
For instance,
- In May 2021, Abbott had received CE Mark for its latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor, making the minimally invasive device available for people in Europe with severe aortic stenosis at high or extreme surgical risk. With the Navitor valve, the company is advancing TAVI (also referred to as TAVR, or transcatheter aortic valve replacement) therapies with innovations including a unique design to prevent blood leaking around the valve. This approval strengthens the company’s structural heart portfolio of minimally invasive offerings by providing new options and improvements to treat a life-threatening heart condition
Parahita Diagnostic Centre is the dominating player in the Indonesia clinical laboratory services market. The other key players in the market include Eurofins Scientific, Siemens Healthcare GmbH, Abbott, Charles River Laboratories, Laboratory Corporation of America Holdings, Parahita Diagnostic Center, CITO Clinical Laboratory, Brianet, SGS SA, Syneos Health, Prodia, Keralty, among others.
Parahita Diagnostic Centre
Parahita Diagnostic Centre was found in the year 1987, and it has headquarters in Jakarta, Indonesia. It has private ownership. The company engaged in providing a complete, integrated, and trusted Diagnostic Centre with wholehearted service and providing technology-based information. The company has service categories such as Healthy Lifestyle, MCU Package, COVID-19, Premarital Package, Diabetes, Hypertension and Heart, Examination Test, Home Services, and Promo. The market-focused category is the Examination Test.
The company has a wide presence across Asia-Pacific. The company has initiated many strategic initiatives to expand its market.
PT Kimia Farma Diagnostika
PT Kimia Farma Diagnostika was founded in 2010, and it has headquarters in Jakarta, Indonesia. It has private ownership. The company is engaged in providing laboratory, clinic, and immunicare health facilities to become an integrated, best, trusted, and largest health service provider in Indonesia. The company has service categories such as laboratory and clinic health facilities which is also the market-focused category.
The company has a presence across Asia-Pacific. The company has initiated many strategic initiatives to expand its market.
Abbott
Abbott was founded in the year 1888, and it has headquarters in Illinois, U.S. It has public ownership. The company engaged in creating breakthrough products– in diagnostics, medical devices, nutrition, and branded generic pharmaceuticals– that help the community lead healthier lives and make a lasting impact on health. The company has business segments such as Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices under which Diagnostic Products are the market-focused segment. Core Laboratory, Molecular, Point of Care, and Rapid Diagnostics are the company's product categories under which Rapid Diagnostics is the market-focused category.
For instance,
- In June 2021, Abbott announced it had received CE Mark and Health Canada approval for its Amplatzer Steerable Delivery Sheath, which is used with its market-leading Amplatzer Amulet Left Atrial Appendage (LAA) Occluder. Abbott's Amplatzer Amulet has long been the LAA occlusion device of choice in Europe and Canada to reduce the risk of stroke and eliminate the need for blood-thinning medication in patients with atrial fibrillation. This innovation advances the performance of companies Amplatzer Amulet device and offers patients a much-needed treatment option to help manage stroke risk from atrial fibrillation
The company has a wide presence across North America, South America, Europe, Asia-Pacific, Middle East, and South Africa. The company has various subsidiaries like Abbott Administration Inc(Delaware), Abbott Cardiovascular Systems Inc.(California), Abbott Home Infusion Services of New York, Inc. (New York), Abbott Laboratories (Puerto Rico) Incorporated, EAS Australia Pty Ltd(Australia), Abbott (Cambodia) LIC., Abbott Laboratories A/S(Denmark) among others.
